(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
05 May 2022 (05.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/094501 A1

(51) International Patent Classification:
A61P 37/02 (2006.01) *A61P 37/06* (2006.01)
A61K 35/17 (2015.01)

(21) International Application Number:
PCT/US2021/071302

(22) International Filing Date:
27 August 2021 (27.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/106,770 28 October 2020 (28.10.2020) US

(71) Applicant: **BAYLOR COLLEGE OF MEDICINE** [US/US]; One Baylor Plaza, Houston, Texas 77030 (US).

(72) Inventors: **O'MALLEY, Bert W.**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US). **HAN, Sang Jun**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US). **LONARD, David M.**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US). **NIKOLAI, Bryan**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US). **JAIN, Prashi**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US). **GILAD, Yosef**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US). **DACSO, Clifford**; c/o Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030 (US).

(74) Agent: **EDDY, Sarah, D.**; Norton Rose Fulbright US LLP, 1301 McKinney Suite 5100, Houston, Texas 77010 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** TARGETING OF SRC-3 IN IMMUNE CELLS AS AN IMMUNOMODULATORY THERAPEUTIC FOR THE TREATMENT OF CANCER




FIG. 1

(57) **Abstract:** The present disclosure concerns methods and compositions related to cancer treatment comprising targeting of SRC-3 in immune cells, including T cells such as T regulatory cells. The targeting of SRC-3 in T regulatory cells in particular is effective to eradicate tumors in mammals. In specific cases, the T regulatory cells are subjected to CRISPR *ex vivo* to produce cells suitable for adoptive cell transfer. In some cases, one or more agents that target SRC-3 are also administered to the individual and/or are exposed to the cells prior to administration.

WO 2022/094501 A1